| |
Jakarta, 28 May 2008
Drug Interactions : What You Should Know.
Drug Interactions : What You Should Know.
A drug interaction is a situation in which a substance affects the activity of a drug, i.e. the effects are increased or decreased, or they produce a new effect that neither produces on its own. Typically, interaction between drugs come to mind (drug-drug interaction). However, interactions may also exist between drugs & foods (drug-food interactions), as well as drugs & herbs (drug-herb interactions), drugs & micronutrients, and drugs & content of infusion solutions
Since most drug interactions have undesirable effects, generally speaking, drug interactions are avoided, due to the possibility of poor or unexpected outcomes. However, drug interactions have been deliberately used, such as co-administering probenecid with penicillin prior to mass production of penicillin.
A contemporary example of a drug interaction used as an advantage is the co-administration of carbidopa with levodopa (available as Carbidopa/levodopa). Levodopa is used in the management of Parkinson's disease and must reach the brain in an un-metabolized state to be beneficial. When given by itself, levodopa is metabolized in the peripheral tissues outside the brain, which decreases the effectiveness of the drug and increases the risk of adverse effects. However, since carbidopa inhibits the peripheral metabolism of levodopa, the co-administration of carbidopa with levodopa allows more levodopa to reach the brain un-metabolized and also reduces the risk of side effects.
Drug interactions may be the result of various processes. These processes may include alterations in the pharmacokinetics of the drug, such as alterations in the Absorption, Distribution, Metabolism, and Excretion (ADME) of a drug. Alternatively, drug interactions may be the result of the pharmacodynamic properties of the drug, e.g. the co-administration of a receptor antagonist and an agonist for the same receptor.
Metabolic drug interactions
Many drug interactions are due to alterations in drug metabolism. One notable system involved in metabolic drug interactions is the enzyme system comprising the cytochrome P450 oxidases. For example, There is a significant drug interaction between Ciprofloxacin and Methadone. Cipro may inhibit cytochrome P450 3A4 up to 65%. Since this is the primary enzyme responsible for metabolizing methadone, Cipro may elevate methadone levels significantly. This system may be affected by either enzyme induction or enzyme inhibition, as discussed in the examples below.
Enzyme induction - drug A induces the body to produce more of an enzyme which metabolises drug B. This reduces the effective concentration of drug B, which may lead to loss of effectiveness of drug B. Drug A effectiveness is not altered.
Enzyme inhibition - drug A inhibits the production of the enzyme metabolising drug B, thus an elevation of drug B occurs possibly leading to an overdose.
Bioavailability - drug A influences the absorption of drug B.
Unfortunately, given a tremendous amount of drugs in the market . it is impossible for any drug companies to check out the complete list of compatibility profile of their products with others. Accordingly, clinicians should always scrutinize prescribing information before administering medicine, particularly of new drugs.
Furthermore, the following link may offer some help when one wish to know drug-drug interactions:
http://www.drugs.com/drug_information.html
Drugs-Micronutrient Interaction
The serum concentration of electrolytes, microminerals and vitamins can be modified by certain drugs and should alert the physisians when abnormalities occur.
(APPENDIX)
IV Drugs Incompatibility
Some injectable drugs are not compatible with the content of infusion solutions. Typical examples are Sodium Bicarbonate in Lactated or Acetated Ringer Solutions.
To prevent incompatibilities, it is important to consider all the ways in which medications may interact outside of or inside the body. If you must mix a medication, always follow manufacturer’s instructions as to the correct volume and type of diluent; which solutions it may be added to for "piggy back" administration; and what flush solutions must be used in between administrations to prevent events like precipitation within the patient’s access device (for example, never administering phenytoin into an intravenous line containing dextrose, or never allowing amphotericin B to come into contact with saline solutions). Other issues to consider are the presence of electrolytes (e.g. potassium chloride) mixing into continuous infusions, such as in a piggyback situation. If mixing medications in a syringe for bolus administration (IV push), assure that they are compatible when combined in a syringe. If consulting a drug reference is not helpful, contact the pharmacy, which has access to additional compatibility information.
Be on alert for medications with a known history of frequent incompatibilities when they come into contact with other drugs. Among the drugs most often incriminated in incompatibilities are furosemide (Lasix), phenytoin (Dilantin), heparin, midazolam (Versed), and diazepam (Valium) when used in IV admixtures.
Drawbacks of PVC
In addition to IV drugs compatibility, clinicians should know that some important issues raise when using PVC as container of infusion solutions. Plasticized polyvinyl chloride (PVC) is one of the most widely used polymeric materials in medical and related fields. In the medical field, flexible PVC is used for the blood storage bags, blood tubing used during hemodialysis, endotracheal tubes, intravenous solution dispensing sets, as well as for drug product storage and packaging. PVC is a rigid polymer, so plasticizers are added to increase its flexibility. Phthalic acid esters, mainly di-(2-ethylhexyl) phthalate (DEHP), are the most preferred plasticizers used in the medical field. Since these additives are not covalently bound to the polymer, there is a possibility for migration of the plasticizer from the matrix. The migration of DEHP from the PVC bags into the solution has been a major concern for many years. The toxicity of DEHP and PVC has raised serious questions about their use. This separation of DEHP from the PVC is called leaching. Leaching occurs when some drugs such as paclitaxel or tamoxifen are administered in PVC bag.
Another concern of using PVC bags are sorption and loss of drug from PVC bags:
- Kowaluk et al. examined interactions between 46 injectable drug products and Viaflex (PVC) infusion bags. Study results showed that sorption increases as drug concentration increases
- Migration of drug into plastic may lead to subtherapeutic drug concentrations eg.insulin, vit A, acetate, diazepam and nitroglycerin.
Maillard Reaction
Although it is not drug-drug interaction, it is important to address this issue. The Maillard reaction is a chemical reaction between an amino acid and a reducing sugar, usually requiring heat. Like caramelization, it is a form of non-enzymatic browning. The reactive carbonyl group of the sugar reacts with the nucleophilic amino group of the amino acid, and forms a variety of interesting but poorly characterized molecules responsible for a range of odors and flavors. Maillard reaction occurs when amino acids and glucose are contained in single bag. Since amino acids and glucose should be given simultaneously, a clever approach is to produce a dual-chamber bag where glucose and amino acids are separated. They are premixed prior to administration.
Further Readings:
- Center for Drug Evaluation and Research (CDER). In Vivo Drug Metabolism/Drug Interaction Studies - Study Design, Data Analysis, and Recommendations for Dosing and Labeling. 1999
- Brazier NC, Levine MA. Drug-herb interaction among commonly used conventional medicines: a compendium for health care professionalsAmerican Journal of Therapeutics 2003; 10(3): 163-169
- http://www.drugs.com/drug_information.html
- Soo An Choi. The role of pharmacist in NST. Proceedings of 11th PENSA Congress. pp256-258.
- Kowaluk EA, Roberts MS, Blackburn HD, Polack AE. Interactions between drugs and polyvinyl chloride infusion bags. Am J Hosp Pharm.1981;38(9):1308-14
- Larry K. Fry and Lewis D. Stegink Formation of Maillard Reaction Products in Parenteral Alimentation Solutions J. Nutr. 1982 112: 1631-1637
- Stadler RH, Blank I, Varga N, Robert F, Hau J, Guy PA, Robert MC, Riediker S. Acrylamide from Maillard reaction products. Nature. 2002 Oct 3;419(6906):449-50.
Appendix 1 Drug Therapy Associated with Micronutrient Abnormalities
|
↓ Calcium
|
aminoglycosides, bisphosphonates, corticosteroids, H2 receptor antagonists, loop diuretics ; amphotericin B, antacids, carbamazepine, cholestyramine, cisplatin, colchicines, digoxin, doxycycline, ethosuximide, foscarnet, Mg oxide/sulfate, minocycline, oxcarbazepine, oxytetracycline, pentamidine, phenobarbital, phenytoin, primidone, Na phosphate, sucralfate, zelodronic acid, zonisamide
|
|
↑ Calcium
|
antiestrogens, estrogens, thiazide diuretics ; aluminium intoxication, aminoiphylline, Ca carbonate, lithium
|
|
↓Magnesium
|
aminoglycosides, corticosteroids, estrogens, loop diuretics, oral contraceptives, tetracyclines,thiazide diuretics; amphotericin B, cholestyramine, cisplatin, cyclosporine, digoxin, foscarnet, hydralazine, methsuximide, pamidronate, penicillamine, raloxifene, Na phosphate, tacrolimus, zoledronic acid
|
|
↑Magnesium
|
Usually associated with intake > 6g/day, Mg-containing antacids/enemas
|
|
↓Phosphorus
|
Thiazide diuretics; alendronate, antacids (Al & Mg-containing), cholestyramine, digoxin, foscarnet, Mg oxide/sulfate, ,pamidronate, sucralfate, theophylline, zoledronic acid
|
|
↑Phosphorus
|
Etidronate, foscarnet, Na phosphate laxatives & enemas
|
|
↓ Potassium
|
Aminoglycosides, loop diuretics, penicillins, salicylates, thiazide diuretics, acetazolamide, amphotericin B, bisacodyl, cisplatin, colchicine, cyclosporine, enoxacin, foscarnet, hydralazine, levodopa, mannitol, pamidronate, Na bicarbonate & phosphates
|
|
↑ Potassium
|
ACE inhibitors, angiotensin, receptor blockers, beta-adrenergic blochers, NSAIDs, potassium sparing diuretics ; cyclosporine, heparin, hypertonic solutions, lithium, pentamidine, succinylcholine
|
|
↓ Sodium
|
Aminoglicosides, loop diuretics, potassium sparing diuretics, thiazide diuretics, salicylates ; acetazolamide, amphotericin B, bisacodyl, captopril, colchicine, foscarnet
|
|
↑ Sodium
|
Hypertonic IV solution, mannitol, Na penicillin G, Na phosphate laxative & enemas
|
|
↓ Zinc
|
ACE inhibitors, corticosteroids, diuretics, estrogens, oral contraceptives, H2 receptor antagonists, reverse transcriptase inhibitors ; cholestyramine, ethambutol, hydralazine, penicillamine
|
|
↓ Chloride
|
Thiazide diuretics, loop diuretics
|
|
↑ Chloride
|
Spironolactone, triamterene
|
Appendix 2 Drug-induced Nutrient Depletion
|
Drug Class
|
Nutrients Depleted
|
|
5-aminosalacylic acid derivatives
|
Folic acid
|
|
ACE inhibitors
|
Zinc
|
|
Aminoglycosides
|
Mg, K, Ca, Na
|
|
Barbiturates
|
Biotin, Ca, folic acid, Vitamin D & K
|
|
Corticosteroids
|
Ca, Folic acid, Mg, K, Selenium, Vit C & D, Zinc
|
|
Estrogens
|
Mg, vitamin B2/B6 & C, Zinc
|
|
H2 receptor antagonists
|
Ca, Folic acid, Iron, Vitamin B12 & D, Zinc
|
|
Loop diuretics
|
Ca, Mg, K, Na, Vitamin B1/B6 & C, Zinc
|
|
Magnesium and aluminium antacids
|
Ca, P
|
|
NSAIDs
|
Folic acid
|
|
Oral contraceptives
|
Folic acid, Mg, Tryptophan, Tyrosine, Vitamin B2/B3/B6/B12 & C, Zinc
|
|
Proton pump inhibitors
|
Vitamin B12
|
|
Reverse transcript inhibitors
|
Carnitine, Copper, Vitamin B12, Zinc
|
|
Thiazides diuretics
|
Mg, P, K, Na, Zinc
|
|
Tricyclic antidepressants
|
Vitamin B2
|
|
Miscellaneous Drugs
|
Nutrition Depleted
|
|
Acetaminophen
|
Glutathione
|
|
Amphotericin B
|
Ca, Mg, K, Na
|
|
Aspirin
|
Folic acid, Iron, K, Na, Vitamin C
|
|
Bisacodyl
|
K, Na
|
|
Chlorpromazine
|
Vitamine B2
|
|
Cholestyramine
|
Beta-carotene, Ca, Folic acid, Iron, Mg, P,
Vitamin A/B12/D/E/K, Zinc
|
|
Cisplatin
|
Ca, Mg, K
|
|
Clonidine
|
Zinc
|
|
Colchicine
|
Beta-carotene, Ca, K, Na, Vitamin B12
|
|
Colestipol
|
Beta-carotene, Folic acid, Iron, Vitamin A/B12/D/E
|
|
Cyclosporine
|
Mg, K
|
|
Digoxin
|
Ca, Mg, P, Vitamin B1
|
|
Fenofibrate
|
Vitamin E
|
|
Foscarnet
|
Ca, Mg, P, K
|
|
Gemfibrozil
|
Vitamin E
|
|
Hydralazine
|
Vitamin B6
|
|
Indomethacin
|
Folic acid, Iron
|
|
Levodopa
|
K
|
|
Metformin
|
Folic acid, Vitamin B12
|
|
Methotrexate
|
Folic acid
|
|
Methyldopa
|
Zinc
|
|
Orlistat
|
Beta-carotene, Vitamin D & E
|
|
Penicillamine
|
Copper, Mg, Vitamin B6, Zinc
|
|
Potassium chloride (timed-release)
|
Vitamin B12
|
|
Primidone
|
Biotin, Folic acid, Vitamin D & K
|
|
Raloxifene
|
Mg, Vitamin B2/B6/C, Zinc
|
|
Salsalate
|
Folic acid
|
|
Theophylline
|
P, Vitamin B1/B6
|
|
Thioridazine
|
Vitamin B2
|
|
Triamterene
|
Ca, Folic acid, Zinc
|
|
Valproic acid
|
Carnitine, Folic acid
|
|
Zonisamide
|
Biotin, Inositol, Vitamin B1/B2/B3/B6/B12 & K
|
Appendix 3 Clinically Significant Drug-Food Interactions
|
Drug
|
Interaction
|
Possible Clinical Outcome
|
|
Tetracycline
|
Decreased bioavailability with milk and dairy products
|
Therapeutic failure
|
|
Ciprofloxacin
|
Decreased bioavailability with milk and dairy products
|
Therapeutic failure
|
|
Azithromycin
|
Decreased bioavailability with food
|
Therapeutic failure
|
|
Itraconazole
|
Decreased bioavailability with food
|
Possible therapeutic failure
|
|
Penicillamine
|
Decreased bioavailability with food
|
Therapeutic failure
|
|
Didanosine
|
Food decreases bioavailability
|
Therapeutic failure
|
|
Indinavir
|
Food decreases bioavailability
|
Therapeutic failure
|
|
Saquinavir
|
Garlic (allicin) decreases bioavailability
|
Decreased antiviral activity
|
|
Atiovaquone
|
Food increases bioavailability
|
Increased efficacy with meals
|
|
Lovodopa
|
Protein decreases transport into the brain
|
Decreased efficacy
|
|
Theophylline
|
Fatty food increases absorption
|
Possible dose dumping toxicity
|
|
Warfarin
|
Vitamin K rich foods antagonize the anticoagulants
|
Effect decreased anticoagulation
|
|
Cyclosporine
|
Food and grapefruit juice increase plasma levels
|
Possible toxicity, lower doses
|
|
Alendronate
|
Food decreases bioavailability
|
Therapeutic failure
|
|
MAO inhibitors
|
Increased tyramine levels
|
Hypertensive crisis
|
|
Terfanadine
|
Grapefruit juice increases
|
Qtc prolongation plasma level
|
|
Felodipine
|
Increased bioavailability
|
Increased adverse effects
|
|
Diuretics
|
Food decreases bioavailability
|
Therapeutic failure
|
|
Spironolactone
|
Food decreases bioavailability
|
Increased efficacy with meals
|
|
Propranolol
|
Increased bioavailability
|
Increased adverse effects
|
Iyan Darmawan, MD
Medical Director
iyan@ho.otsuka.co.id
|
|